The company manufactures and sells vaccines, health products, feed supplements, and therapeutics for poultry, large and small ruminants, and companion animals
For MS patients taking disease-modifying therapies (DMTs), specific considerations include: Oral DMTs (fingolimod, siponimod, ozanimod, ponesimod, teriflunomide, dimethyl fumarate, diroximel fumarate): Semaglutide may delay absorption
This policy is designed as a temporary measure to ensure continuity of care when FDA-approved drugs are not commercially available
Several companies have GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists in phase 1 studies, including SCO-094 (Scohia Pharma), VK2735 (Viking Therapeutics) and CT-388 (Carmot Therapeutics)